---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-203530"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:42:34.778965+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout

## Summary
- Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
- Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.
- OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.
- CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise.

## SEC filing metadata
- accession: 0001193125-25-203530
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/0001193125-25-203530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/opk-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-203530
- JSON: https://secwatch.observer/filing/0001193125-25-203530.json
- Plain text: https://secwatch.observer/filing/0001193125-25-203530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.